Time to achieve a patient acceptable symptom state in myasthenia gravis

Time to achieve a patient acceptable symptom state in myasthenia gravis

IntroductionThe patient acceptable symptom state (PASS) is a reliable way to characterize a patient’s satisfaction with their disease state in a “Yes”/“No” dichotomous manner. There is limited data on the time required to reach an acceptable state in Myasthenia Gravis (MG). We aimed to determine the...

Full description

Bibliographic Details
Main Authors:	Rodrigo Martinez-Harms, Carolina Barnett, Vera Bril
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Neurology
Subjects:	myasthenia gravis patient acceptable symptom state myasthenia gravis impairment index single simple question satisfactory disease status
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1187189/full

Similar Items

Novel Treatments in Myasthenia Gravis
by: Deepak Menon, et al.
Published: (2020-06-01)

Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
by: Courtney Townsel, et al.
Published: (2016-03-01)

Pediatric ocular myasthenia gravis: Case report and literature review
by: Adriana Solano, et al.
Published: (2019-01-01)

Disease severity assessment and short-term outcome in patients with myasthenia gravis
by: Deepthi Vemuri, et al.
Published: (2020-01-01)

Myasthenia gravis and related disorders : 11th International Conference /
by: Kaminski, Henry J., et al.
Published: (2008)

The miracle of St. Alfege’s Hospital and the history of the treatment of myasthenia gravis
by: Cristina Croitoru, et al.
Published: (2017-03-01)

Fetal Surveillance in Pregnancies with Myasthenia Gravis
by: Brîndușa Ana Cimpoca-Raptis, et al.
Published: (2021-11-01)

Pregnancy with Myasthenia Gravis
by: Ninuk Dwi ariningtyas, et al.
Published: (2020-01-01)

Thymectomy in 19 Cases of Myasthenia Gravis in 4 Years Follow up
by: Saeed Mahmoudi, et al.
Published: (2002-09-01)

Neuropsychiatric symptoms in patients with thymoma-associated and non-thymoma myasthenia gravis
by: Carla Freeman, et al.
Published: (2014-07-01)

Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
by: Cao, M
Published: (2021)

Myasthenia gravis in children: analysis of 18 patients
by: Morita Maria da Penha A., et al.
Published: (2001-01-01)

Management of Juvenile Myasthenia Gravis
by: Karen O'Connell, et al.
Published: (2020-07-01)

Minimal Manifestation Status Indicates a Stable State in Myasthenia Gravis: A Quantitative Study
by: Ping Jiang, et al.
Published: (2022-05-01)

Clinical characteristics and outcomes of COVID-19 infection among myasthenia gravis patients in a national referral hospital in Indonesia
by: Fitri Octaviana, et al.
Published: (2023-09-01)

Prospective study of stress, depression and personality in myasthenia gravis relapses
by: Anca Bogdan, et al.
Published: (2020-06-01)

Late-onset myasthenia gravis: Is it a different clinical entity?
by: Hulya Tireli, et al.
Published: (2021-01-01)

Clinical characteristics of late-onset myasthenia gravis
by: Chenjing Sun, et al.
Published: (2024-04-01)

Национален консенсус за диагностика и лечение на myasthenia gravis
by: Ivan Milanov, et al.
Published: (2021-03-01)

Национален консенсус за диагностика и лечение на myasthenia gravis
by: Ivan Milanov, et al.
Published: (2023-04-01)

Uncontrolled recurrent myasthenia gravis exacerbations secondary to chronic gabapentin use
by: Jason L. Chien, et al.
Published: (2019-07-01)

Management of myasthenia gravis during pregnancy: A report of eight cases
by: Shi Beibei, et al.
Published: (2018-04-01)

Ocular myasthenia gravis and thymoma
by: Victor Alegre-Ituarte, et al.
Published: (2022-09-01)

Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice
by: Lukas Theissen, et al.
Published: (2024-03-01)

New‐Onset Myasthenia Gravis Mimics Spinal Cord Injury After Zenker's Diverticulum Repair
by: Steffen E. Meiler, et al.
Published: (2023-04-01)

Generalized Myasthenia Gravis Diagnosed After Blepharoplasty
by: Murat Alemdar, et al.
Published: (2021-12-01)

PLASMAPHERESIS IN THE TREATMENT OF MYASTHENIA GRAVIS: OUTCOME AND COMPLICATIONS
by: Maryam Abbas, et al.
Published: (2021-04-01)

Sotalol‐induced generalized and ocular myasthenia gravis
by: Mohammadbagher Sharifkazemi, et al.
Published: (2019-09-01)

Novel Immunotherapies for Myasthenia Gravis
by: Nair SS, et al.
Published: (2023-04-01)

Concomitant symptom and medicine related exacerbation in myasthenia gravis: how to analyse the clinical causal relationship
by: Hai⁃feng LI
Published: (2012-04-01)

Assessment of fatigue and autonomic dysfunction in myasthenia gravis – case report
by: Klaudia Kwiatkowska, et al.
Published: (2019-05-01)

Altered serum levels of cytokines in patients with myasthenia gravis
by: Shu-Li Wei, et al.
Published: (2024-01-01)

Role of thymus on prognosis of myasthenia gravis in Turkish population
by: Hulya Tireli, et al.
Published: (2020-10-01)

Physiotherapy in myasthenia gravis
by: Klaudia Kwiatkowska, et al.
Published: (2018-12-01)

Physiotherapy in myasthenia gravis
by: Klaudia Kwiatkowska, et al.
Published: (2018-12-01)

Dysphagia as a Main Symptom of Myasthenia Gravis in a Middleaged Adult Male: A Case Report
by: Payam Sariaslani, et al.
Published: (2023-06-01)

The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review
by: Jeannine M. Heckmann, et al.
Published: (2022-02-01)

Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
by: Sudulagunta, Sreenivasa Rao, et al.
Published: (2016-10-01)

Myasthenia gravis therapy with individualized homeopathy: A case report
by: Vitalie Văcăraș, et al.
Published: (2020-12-01)

The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis
by: Yanchen Xie, et al.
Published: (2017-05-01)